Review of TA86; Imatinib for gastrointestinal stromal tumours, and TA209; Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours

The Institute was proposing that both TA86 and TA209 should be moved to the static list.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

Consequently, both TA86 and TA209 will be moved to the static list.  Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.

October 2013